Media

The Biotechnology Innovation Organization (BIO) is pleased to announce that the Honorable Dennis McGinn, Assistant Secretary of the Navy, Energy, Installations...
BIO Executive Vice President for Health Policy Dan Durham released the following statement regarding yesterday’s proposed Part B Drug Payment Model and...

Press Releases

May 7 2015
Washington DC, May 15, 2015 – The Biotechnology Industry Organization (BIO) announced today that the Industrial Biotechnology (Mary Ann Liebert, Inc.,...
May 7 2015
WASHINGTON, D.C. (May 7, 2017) Farmers around the world who use seeds improved with biotechnology continue to benefit economically while improving the...
May 4 2015
EPA’s delays in rulemaking for the Renewable Fuel Standard (RFS) over the past two years have chilled necessary investment in advanced and cellulosic...
May 1 2015
Washington, D.C. (May 1, 2015) – Today, the Biotechnology Industry Organization (BIO) applauds Rep. Pat Meehan (R-PA) for introducing the Partnerships...
May 1 2015
Washington, DC, Friday, May 1, 2015 – Today, the Biotechnology Industry Organization (BIO) released the following statement on the Medicare Part D Data...
May 1 2015
Washington, DC, Friday, May 1, 2015 – Today, the Biotechnology Industry Organization (BIO) released the following statement on the Medicare Part D Data...
Apr 30 2015
Washington, D.C. (April 30, 2015) – Today, the 2015 BIO International Convention® Buzz of BIO contest winners were announced, recognizing highly...
Apr 30 2015
WASHINGTON, D.C. (Thursday, April 30, 2015) - Shane Kovacs, Executive Vice President & Chief Financial Officer of PTC Therapeutics, Inc., provided...
Apr 29 2015
Washington, D.C. (April 29, 2015) – The Biotechnology Industry Organization (BIO) today issued the following statement regarding the introduction of...


Biotechnology News

Feb 8 2016 - 12:27pm
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s announced today that its US subsidiary, Promius PharmaTM, LLC, U.S. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), has received approval for Sernivo™ (betamethasone dipropionate) Spray, 0.05% from the U.S. Food and Drug Administration (FDA). Sernivo Spray, a prescription topical steroid, is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older. The commercial launch of the product is planne

Feb 8 2016 - 12:27pm
LONDON--(BUSINESS WIRE)--AstraZeneca and MedImmune, its global biologics research and development arm, today announced publication in The Lancet Oncology of a Phase Ib study (study 006), showing antitumour activity of combination treatment with durvalumab and tremelimumab, in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), irrespective of PD-L1 status.1 In a cohort of 26 patients treated with durvalumab 10-20 mg/kg plus tremelimumab 1 mg/kg, and followed for ≥24

Feb 8 2016 - 12:27pm
PRINCETON, N.J. & PARIS--(BUSINESS WIRE)--Regulatory News: STENTYS (FR0010949404 — STNT – éligible PEA PME) (Paris:STNT), société de technologie médicale qui commercialise le premier et le seul stent auto-apposant coronaire, annonce ce jour les premiers accords de distribution de son stent actif pour le traitement des artères sous le genou (BTK – below-the-knee) en Allemagne et en Belgique, ce qui en fait le premier stent actif auto-expansif commercialisé dans cette indication en Europe. Le ste

Feb 8 2016 - 12:27pm
PRINCETON, N.J. & PARIS--(BUSINESS WIRE)--Regulatory News: STENTYS (FR0010949404 — STNT) (Paris:STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces the first distribution agreements for its drug-eluting stent for treating BTK (Below-The Knee) arteries in Germany and Belgium, making it the first self-expanding drug-eluting stent commercialized for this indication in Europe. The STENTYS stent obtained CE Marking for the BTK

Feb 8 2016 - 12:27pm
LONDRES--(BUSINESS WIRE)--AstraZeneca et MedImmune, sa branche internationale de recherche et de développement de produits biologiques, ont annoncé aujourd’hui la publication dansThe Lancet Oncology d’une étude de Phase Ib (Étude 006), qui indique une activité antitumorale de la thérapie combinée, associant le durvalumab et le tremelimumab, chez les patients qui souffrent d’un cancer bronchique non à petites cellules (CBNPC), localement avancé ou métastatique, indifféremment du statut PD-L1.1 P

Feb 8 2016 - 12:27pm
LONDON--(BUSINESS WIRE)--AstraZeneca und MedImmune, sein globaler Forschungs- und Entwicklungszweig für Biologika, meldeten heute die Veröffentlichung einer Phase-Ib-Studie (Studie 006) in der Fachzeitschrift The Lancet Oncology , in der eine tumorhemmende Wirkung der Kombinationstherapie mit Durvalumab plus Tremelimumab bei Patienten mit lokal fortgeschrittenem oder metastasierendem, nicht-kleinzelligem Lungenkrebs (NSCLC) nachgewiesen wurde, und zwar unabhängig vom PD-L1-Status.11 In einer Ko

Feb 8 2016 - 12:27pm
LONDRES--(BUSINESS WIRE)--A AstraZeneca e a MedImmune, seu braço global de desenvolvimento e pesquisa biológica, anunciou hoje a publicação na The Lancet Oncology de um estudo da Fase Ib (estudo 006) mostrando a atividade antitumoral do tratamento combinado com durvalumab e tremelimumabe em pacientes com câncer no pulmão de não pequenas células (NSCLC) localmente avançado ou metastático, independentemente do seu estado de PD-L1.1 Em uma coorte de 26 pacientes tratados com de durvalumab 10-20 mg

Feb 8 2016 - 12:27pm
LONDRA--(BUSINESS WIRE)--AstraZeneca e MedImmune, la sua branca di ricerca biologica e di sviluppo globale, hanno annunciato oggi la pubblicazione in The Lancet Oncology di uno studio di fase Ib (studio 006) che dimostra l'attività antitumorale del trattamento combinato di durvalumab e tremelimumab in pazienti con tumore ai polmoni non di piccole cellule localmente avanzato o metastatico (NSCLC), indipendentemente dallo stato del PD-L1. Il testo originale del presente annuncio, redatto nella li

Feb 8 2016 - 12:27pm
LONDRES--(BUSINESS WIRE)--AstraZeneca y MedImmune, su división global de investigación y desarrollo en medicamentos biológicos, anunció hoy la publicación en The Lancet Oncology de un estudio de Fase Ib (estudio 006), que muestra la actividad antitumoral del tratamiento de combinación de durvalumab y tremelimumab, en pacientes con cáncer de pulmón no microcítico avanzado localmente o metastásico (NSCLC), independientemente de la condición de PD-L1.1 En un cohorte de 26 pacientes tratados con du

Feb 8 2016 - 12:27pm
BORDEAUX, France & BOSTON--(BUSINESS WIRE)--Regulatory News: IMPLANET (Euronext : IMPL, FR0010458729, éligible PEA-PME), société de technologies médicales spécialisée dans les implants rachidiens et les implants de chirurgies du genou, annonce la nomination de Brian T. Ennis au poste de Président de Implanet America. À ce titre, il prend la direction de Implanet America et a pour objectif d’optimiser sa structure organisationnelle afin d’accélérer l’adoption et la progression de la technologie